Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 1/2003

01-01-2003 | Adis Drug Profile

Lansoprazole

In the Management of Gastroesophageal Reflux Disease in Children

Author: Lesley J. Scott

Published in: Pediatric Drugs | Issue 1/2003

Login to get access

Abstract

  • ▲ Lansoprazole, a proton pump inhibitor, inactivates the H+/K+-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH.
  • ▲ After 8–12 weeks’ treatment with lansoprazole, all children (n = 27) with esophagitis at baseline were healed (confirmed by endoscopy) and 76% of 62 evaluable children experienced improvements in overall gastroesophageal reflux disease (GERD) symptoms. In this noncomparative trial, 66 children (aged 1–11 years) with GERD with or without esophagitis received oral lansoprazole 15 or 30mg once daily dependent on their weight.
  • ▲ The drug is generally well tolerated in children with GERD. In the largest study, the most common treatment-related adverse events occurring during therapy were constipation and headache.
Literature
1.
Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000 Oct; 39(4): 295–309PubMedCrossRef
2.
Orenstein SR, Izadnia F, Khan S. Gastroesophageal reflux disease in children. Gastroenterol Clin North Am 1999; 28(4): 947–69PubMedCrossRef
3.
Del Rosario JF, Orenstein SR. Common pediatric esophageal disorders. Gastroenterologist 1998; 6(2): 104–21PubMed
4.
Jung AD. Gastroesophageal reflux disease in infants and children. Am Fam Physicians 2001; 64: 1853–60
5.
Fendrick AM. Management of patients with symptomatic gastroesophageal reflux disease: a primary care perspective. Am J Gastroenterol 2001; 96(8 Suppl.): S29–33PubMedCrossRef
6.
De Vault KR, Castell DO, The Practice Committee of the American College of Gastroenterology. Practice guidelines: updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94(6): 1434–42CrossRef
7.
Dent J, Brub J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 Suppl. 2: S1–16CrossRef
8.
Rudolph CD, Mazur LJ, Liptak GS, et al. Pediatric GE reflux clinical practice guidelines. J Pediatr Gastroenterol Nutr 2001; 32 Suppl. 2: S1–31PubMedCrossRef
9.
Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44(2): 225–50PubMedCrossRef
10.
Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54(3): 473–500PubMedCrossRef
11.
Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001; 61(12): 1801–33PubMedCrossRef
12.
Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48(3): 404–30PubMedCrossRef
13.
Book L, Chiu YL, Pilmer B, et al. Effect of lansoprazole on intraesophageal pH in children with pathologic acid reflux [abstract no. S1276]. Gastroenterology 2002 Apr; 122 Suppl. 1: A197
14.
Book L, Chiu Y, Pilmer B, et al. Effect of lansoprazole on intraesophageal pH in children with pathologic acid reflux [poster]. Digestive Disease Week; 2002 May 19–22; San Francisco
15.
Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002 May; 71(5): 359–67PubMedCrossRef
16.
Wolf A, Wettstein AR, Drewe J, et al. Lansoprazole achieves faster control of intragastric acidity than pantoprazole or omeprazole after a single dose [abstract no. 6041]. Gastroenterol 2000; 118 Suppl. 2 (Pt. 2): A1325
17.
Blum RA, Shi H, Karol MD, et al. The comparative effects of lansoprazole, omeprazole and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 1013–23PubMedCrossRef
18.
Thomson A, Appelman S, Sridhar S, et al. Lansoprazole or pantoprazole: which PPI provides faster and more profound acid suppression [abstract no. P0126]. Gut 1999; 45 Suppl. V: A106
19.
Janczewska I, Sagar M, Sjostedt S, et al. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1239–43PubMedCrossRef
20.
Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001 Sep; 15(9): 1397–402PubMedCrossRef
21.
Gremse D, Winter H, Tolia V, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S319–26PubMedCrossRef
22.
Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S308–18PubMedCrossRef
23.
24.
Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000 Nov; 32(8): 660–6PubMedCrossRef
25.
Stolte M, Vieth M, Schmitz JM, et al. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 2000; 35: 1125–30PubMedCrossRef
26.
Stolte M, Meining A, Seifert E, et al. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Pract 2000; 196: 9–13PubMedCrossRef
27.
Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S300–7PubMedCrossRef
Metadata
Title
Lansoprazole
In the Management of Gastroesophageal Reflux Disease in Children
Author
Lesley J. Scott
Publication date
01-01-2003
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 1/2003
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/00128072-200305010-00005

Other articles of this Issue 1/2003

Pediatric Drugs 1/2003 Go to the issue

Adis Drug Profile

Formoterol Delivered by Turbuhaler®

Review Article

The Use of Proton Pump Inhibitors in Children

Adis Drug Profile

Formoterol Delivered by Turbuhaler®

Review Article

Quality of Life in Children and Adolescents with Cystic Fibrosis

Therapy In Practice

Adolescent Smoking

Therapy In Practice

Spasticity Associated with Cerebral Palsy in Children